CIK 0001672619 · Non-accelerated filer
Enliven Therapeutics, Inc.
Sign in to watch- Ticker
- ELVN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811523849
- Phone
- 650-547-5814
- Business address
- 205 PARK ROAD, BURLINGAME, CA, 94010
- Former names
- IMARA Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,230,845
- in 7 filings, $1.6M under 10b5-1 plans
Net −$2,230,845. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 37 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-19 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +6,018 | $14.85 | $89K | 44,018 |
| 2026-10-19 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −6,018 | $38.48 | $232K | 38,000 |
| 2026-10-19 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −6,018 | 175,000 | ||
| 2026-09-17 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +3,982 | $14.85 | $59K | 44,018 |
| 2026-09-17 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −3,535 | $50.03 | $177K | 40,483 |
| 2026-09-17 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −2,194 | $50.72 | $111K | 38,289 |
| 2026-09-17 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −289 | $51.49 | $15K | 38,000 |
| 2026-09-17 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −3,982 | 181,018 | ||
| 2026-08-17 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −4,630 | $58.35 | $270K | 41,424 |
| 2026-08-17 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −1,388 | $59.35 | $82K | 40,036 |
| 2026-07-17 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +1,072 | $2.48 | $3K | 52,072 |
| 2026-07-17 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −324 | $49.97 | $16K | 51,748 |
| 2026-07-17 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −369 | $51.48 | $19K | 51,379 |
| 2026-07-17 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −2,564 | $52.32 | $134K | 48,815 |
| 2026-07-17 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −2,638 | $53.38 | $141K | 46,177 |
| 2026-07-17 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −123 | $53.87 | $7K | 46,054 |
| 2026-07-17 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −1,072 | 84,966 | ||
| 2026-06-17 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +6,018 | $2.48 | $15K | 57,018 |
| 2026-06-17 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −1,379 | $42.79 | $59K | 55,639 |
| 2026-06-17 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −3,401 | $43.86 | $149K | 52,238 |
Page 1 of 9 · 170 trades